BARDA-Supported Molecular Diagnostic Test for Six Biothreat Pathogens Receives FDA-Clearance
Sepsis being researched at Butler Memorial Hospital
T2 Biosystems Gets FDA 510(k) Clearance for Biothreat Panel
T2 Biosystems Gets FDA 510(k) Clearance for Biothreat Panel
T2 Biosystems’ Candida Auris Test Gets Breakthrough Device Designation
T2 Biosystems, Vanderbilt University Medical Center Partner on Prospective Bacterial Sepsis Dx Study
T2 Biosystems and VUMC partner to assess T2Bacteria Panel
T2 Biosystems seeking FDA breakthrough device designation for Candida auris test
How T2 Biosystems Inc. is utilizing miniaturized magnetic resonance technology for Lyme Disease
Rapid Diagnostic Tests and Their Effect on Antimicrobial Stewardship
T2 Biosystems Readies Biothreat Panel for FDA Submission While Keeping Eye on Sepsis Market
Increasing HAIs due to COVID-19 Stress the Need for a New Approach to Sepsis Diagnostics
